Omega-3 polyunsaturated fatty acids selectively inhibit growth in neoplastic oral keratinocytes by differentially activating ERK1/2

Carcinogenesis

Volumn 34, Issue 12, 2013, Pages 2716-2725

  Nikolakopoulou, Zacharoula ^a   Nteliopoulos, Georgios ^b   Michael Titus, Adina T ^a   Parkinson, Eric Kenneth ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; DOCOSAHEXAENOIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; ICOSAPENTAENOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; KERATINOCYTE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; KERATINOCYTES; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION;

EID: 84888994469     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt257     Document Type: Article

References (54)

1. Pindborg,J.J. (1984) Control of oral cancer in developing countries. A WHO meeting. Bull. World Health Organ, 62, 817-830.
2. Speight,P.M. et al (2006) The cost-effectiveness of screening for oral cancer in primary care. Health Technol. Assess., 10, 1-144, iii.
3. Tabor,M.P. et al (2002) Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am. J. Pathol., 161, 1051-1060.
4. Braakhuis,B.J. et al (2002) Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck, 24, 198-206.
5. Calviello,G. et al (2009) Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr. Cancer, 61, 287-301.
6. Tavani,A. et al (2003) n-3 polyunsaturated fatty acid intake and cancer risk in Italy and Switzerland. Int. J. Cancer, 105, 113-116.
7. Braden,L.M. et al (1986) Dietary polyunsaturated fat in relation to mammary carcinogenesis in rats. Lipids, 21, 285-288.
8. Rose,D.P. et al (1993) Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J. Natl. Cancer Inst., 85, 1743-1747.
9. Ramesh,G. et al (1996) Effect of free fatty acids on two-stage skin carcinogenesis in mice. Cancer Lett., 100, 199-209.
10. Weylandt,K.H. et al (2011) Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-a. Carcinogenesis, 32, 897-903.
11. Lu,Y. et al (2008) Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 β phosphorylation. Mol. Cancer Ther., 7, 3203-3211.
12. Jia,Q. et al (2008) Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice. Cancer Res., 68, 3985-3991.
13. Calder,P.C. (2004) n-3 fatty acids, inflammation, and immunity-relevance to postsurgical and critically ill patients. Lipids, 39, 1147-1161.
14. Biondo,P.D. et al (2008) The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J. Nutr. Biochem., 19, 787-796.
15. Serini,S. et al (2009) Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis, 14, 135-152.
16. Schley,P.D. et al (2007) (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J. Nutr., 137, 548-553.
17. Sun,H. et al (2011) Omega-3 Fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathway. Carcinogenesis, 32, 1518-1524.
18. Schley,P.D. et al (2005) Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Res. Treat., 92, 187-195.
19. Yusufi,A.N. et al (2003) Differential effects of low-dose docosahexaenoic acid and eicosapentaenoic acid on the regulation of mitogenic signaling pathways in mesangial cells. J. Lab. Clin. Med., 141, 318-329.
20. Calviello,G. et al (2004) n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1a induction pathway. Carcinogenesis, 25, 2303-2310.
21. Collett,E.D. et al (2001) n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am. J. Physiol. Cell Physiol., 280, C1066-C1075.
22. Murata,M. et al (2001) Dual action of eicosapentaenoic acid in hepatoma cells: up-regulation of metabolic action of insulin and inhibition of cell proliferation. J. Biol. Chem., 276, 31422-31428.
23. Serini,S. et al (2008) Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression. Apoptosis, 13, 1172-1183.
24. Xia,Z. et al (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 270, 1326-1331.
25. Elder,D.J. et al (2002) The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int. J. Cancer, 99, 323-327.
26. Galve-Roperh,I. et al (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med., 6, 313-319.
27. Pumiglia,K.M. et al (1997) Cell cycle arrest mediated by the MEK/ mitogen-activated protein kinase pathway. Proc. Natl Acad. Sci. USA, 94, 448-452.
28. Stanciu,M. et al (2000) Persistent activation of ERK contributes to glutamate- induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem., 275, 12200-12206.
29. Arita,K. et al (2001) Mechanism of apoptosis in HL-60 cells induced by n-3 and n-6 polyunsaturated fatty acids. Biochem. Pharmacol., 62, 821-828.
30. Lee,M. et al (2007) Docosahexaenoic acid induces apoptosis in CYP2E1- containing HepG2 cells by activating the c-Jun N-terminal protein kinase related mitochondrial damage. J. Nutr. Biochem., 18, 348-354.
31. Rheinwald,J.G. et al (1981) Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res., 41, 1657-1663.
32. Brown,K.W. et al (1987) Malignant progression of an SV40-transformed human epidermal keratinocyte cell line. Br. J. Cancer, 56, 545-554.
33. Dickson,M.A. et al (2000) Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol., 20, 1436-1447.
34. Rheinwald,J.G. et al (2002) A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol. Cell. Biol., 22, 5157-5172.
35. McGregor,F. et al (2002) Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Res., 62, 4757-4766.
36. Pitiyage,G.N. et al (2011) Senescent mesenchymal cells accumulate in human fibrosis by a telomere-independent mechanism and ameliorate fibrosis through matrix metalloproteinases. J. Pathol., 223, 604-617.
37. Vermes,I. et al (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods, 184, 39-51.
38. Rodust,P.M. et al (2009) UV-induced squamous cell carcinoma-a role for antiapoptotic signalling pathways. Br. J. Dermatol., 161 (suppl. 3), 107-115.
39. Gill,G.N. et al (1981) Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature, 293, 305-307.
40. Traverse,S. et al (1994) EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. Curr. Biol., 4, 694-701.
41. Castellano,E. et al (2011) RAS interaction with PI3K: more than just another effector pathway. Genes Cancer, 2, 261-274.
42. Gire,V. et al (2000) PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene, 19, 2269-2276.
43. Kennedy,A.L. et al (2011) Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol. Cell, 42, 36-49.
44. Stanton,P. et al (1994) Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br. J. Cancer, 70, 427-433.
45. Haase,I. et al (2001) A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis. J. Clin. Invest., 108, 527-536.
46. Persons,D.L. et al (1999) Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal- regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res., 5, 1007-1014.
47. Black,H.S. et al (2006) The potential of omega-3 fatty acids in the prevention of non-melanoma skin cancer. Cancer Detect. Prev., 30, 224-232.
48. Finch,A.R. et al (2012) Dual specificity phosphatases 10 and 16 are positive regulators of EGF-stimulated ERK activity: indirect regulation of ERK signals by JNK/p38 selective MAPK phosphatases. Cell. Signal., 24, 1002-1011.
49. Wang,X. et al (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem., 275, 39435-39443.
50. Gulli,L.F. et al (1996) Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ., 7, 173-178.
51. Vigneron,A. et al (2010) p53, ROS and senescence in the control of aging. Aging (Albany. NY)., 2, 471-474.
52. Calder,P.C. (2012) Mechanisms of action of (n-3) fatty acids. J. Nutr., 142, 592S-599S.
53. Heukelom,J. et al (2013) Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer, 13, 84.
54. de Luis,D.A. et al (2013) A randomized clinical trial with two doses of a omega 3 fatty acids oral and arginine enhanced formula in clinical and biochemical parameters of head and neck cancer ambulatory patients. Eur. Rev. Med. Pharmacol. Sci., 17, 1090-1094.